Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.

Phase 2

The University of Texas Health Science Center at San Antonio

Imipramine
Lomustine